Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 3, 2007, Pages 161-166

  Ichihara, Atsuhiro ^a   Kaneshiro, Yuki ^a   Sakoda, Mariyo ^a   Takemitsu, Tomoko ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Ambulatory blood pressure; Intima media thickness; Pleiotropic; Pulse wave velocity

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; LOSARTAN; PLACEBO; VALSARTAN;

ADULT; ARTERY DIAMETER; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; HEART FUNCTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; PLEIOTROPY; PRIORITY JOURNAL; PULSE WAVE; THORAX RADIOGRAPHY; URINARY EXCRETION;

ALBUMINURIA; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CAROTID ARTERIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PULSATILE FLOW; RADIOGRAPHY, THORACIC; TUNICA INTIMA; TUNICA MEDIA;

EID: 34147194757     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31803104e5     Document Type: Article

References (33)

1. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
2. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
3. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
4. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
5. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
6. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
7. Inukai T, Yoshida N, Wakabayashi S, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus. Am J Med Sci. 2005;329:222-227.
8. Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens. 2002;15:9S-13S.
9. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
10. Terpstra WF, May JF, Smit AJ, et al. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens. 2004;22:1309-1316.
11. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23:2155-2163.
12. Mason RP, Walter MF, Trumbore MW, et al. Membrane Antioxidant Effects of the Charged Dihydropyridine Calcium Antagonist Amlodipine. J Mol Cell Cardiol. 1999;31:275-281.
13. Chen L, Haught WH, Yang B, et al. Preservation of Endogenous Antioxidant Activity and Inhibition of Lipid Peroxidation as Common Mechanisms of Antiatherosclerotic Effects of Vitamin E, Lovastatin and Amlodipine. J Am Coll Cardiol. 1997;30:569-575.
14. Kobayashi N, Yanaka H, Tojo A, et al. Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. J Cardiovasc Pharmacol. 1999;34:173-181.
15. Stepien O, Gogusev J, Zhu DL, et al. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol. 1998;31:786-793.
16. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens. 2002;15:321-325.
17. Niwa Y, Ishimoto K, Kanoh T. Induction of superoxide dismutase in leukocytes by paraquat: correlation with age and possible predictor of longevity. Blood. 1990;76:835-841.
18. Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in hemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 2002;17:1513-1517.
19. Ichihara A, Hayashi M, Koura Y, et al. Long-term effects of intensive blood-pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens. 2003;16:959-965.
20. Ichihara A, Hayashi M, Kaneshiro Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis. 2005;45:866-874.
21. Ichihara A, Hayashi M, Koura Y, et al. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens. 2005;19:103-109.
22. Sun K, Daimon M, Watanabe S, et al. The relation of pulse wave velocities measured by oscillometric and tonometric methods and clinical application studies. Jpn J Appl Physiol. 2002;32:81-86.
23. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002;25:359-364.
24. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Ambulatory Blood Pressure Variability and Brachial-Ankle Pulse Wave Velocity in Untreated Hypertensive Patients. J Hum Hypertens. 2006;20:529-536.
25. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens. 2006;20:787-794.
26. Mital S, Loke KE, Slater JP, et al. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts. Am J Cardiol. 1999;83:92H-98H.
27. Zhang X, Xu X, Nasjletti A, et al. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol. 2000;35:195-202.
28. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
29. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
30. Ikeda U, Hojo Y, Ueno S, et al. Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells. J Cardiovasc Pharmacol. 2000;35:887-890.
31. Wada Y, Kato S, Okamoto K, et al. Diltiazem, a calcium antagonist, inhibits matrix metalloproteinase-1 (tissue collagenase) production and collagenolytic activity in human vascular smooth muscle cells. Int J Mol Med. 2001;8:561-566.
32. Block LH, Matthys H, Emmons LR, et al. Ca(2+)-channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci U S A. 1991;88:9041-9045.
33. Kataoka C, Egashira K, Ishibashi M, et al. Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Am J Physiol Heart Circ Physiol. 2004;286:H768-H774.